论文部分内容阅读
目的探讨血清肿瘤标记物对胰腺癌诊断及随访的临床价值。方法对53例胰腺癌患者和39例胰腺良性疾病患者进行四项血清肿瘤标记物检测,并对18例胰腺癌术后患者进行随访。结果胰腺癌组血清肿瘤标记物水平均高于胰腺良性病组(P<0.05),4项血清肿瘤标记物中以CA199敏感性和特异性最高,分别为71.69%和74.35%,联合检测可提高其敏感性和特异性,分别为88.69%和89.74%。胰腺癌未切除的患者肿瘤标记物水平术后未降至正常,胰腺癌切除后肿瘤标记物水平降至正常的患者在随访中再升高后出现肿瘤复发或转移,且肿瘤标记物在影像学检查证实复发数月前已出现升高。结论血清肿瘤标记物联合检测可提高胰腺癌的诊断率,有助于早期胰腺癌诊断,并可用于判断治疗效果和预后、监测肿瘤复发和转移。
Objective To investigate the clinical value of serum tumor markers in the diagnosis and follow-up of pancreatic cancer. Methods Four serum tumor markers were detected in 53 patients with pancreatic cancer and 39 patients with benign pancreatic diseases, and 18 patients with postoperative pancreatic cancer were followed up. Results The levels of serum tumor markers in pancreatic cancer were higher than those in benign pancreatic tissues (P <0.05). The sensitivity and specificity of CA199 in the four serum tumor markers were 71.69% and 74.35%, respectively, and the combined detection could be improved The sensitivity and specificity were 88.69% and 89.74% respectively. Patients with unresectable pancreatic cancer did not have normal levels of tumor markers postoperatively, and those with normal levels of tumor markers after resection of pancreatic cancer showed recurrence or metastasis after follow-up. The tumor markers were detected in imaging Check to confirm the recurrence of a few months ago has risen. Conclusion Combined detection of serum tumor markers can improve the diagnostic rate of pancreatic cancer, which is helpful for the diagnosis of early pancreatic cancer and can be used to determine the therapeutic effect and prognosis, and to monitor the recurrence and metastasis of the tumor.